Medicine Recommendations

Erectile Dysfunction in patients who have not responded to at least 2 other PDE5 inhibitors

Erectile Dysfunction in patients who are intolerant to or have a contra-indication toPDE5 inhibitors

Erectile Dysfunction

Erectile Dysfunction

Treatment of erectile dysfunction in adult men who are unable to tolerate sildenafil and tadalafil

For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.

Urinary Retention

Postpartum haemorrhage

Premature ejaculation

MHRA Drug Safety Update - Citalopram and escitalopram: QT interval prolongation

Treatment of premature ejaculation (PE) in men 18-64 years of age

Urinary frequency, urgency, and incontinence

Benign prostatic hyperplasia

BJUI - Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia

Premature ejaculation

Contraception

MHRA Drug Safety Update - Intrauterine contraception: uterine perforation—updated information on risk factors

MHRA Drug Safety Update - Levonorgestrel-releasing intrauterine systems: prescribe by brand name

Treatment of primary premature ejaculation in adult men

Termination of pregnancy

Symptoms of overactive bladder (NICE TA290)

NICE TA290 - Mirabegron for treating symptoms of overactive bladder

*FOR BLACKPOOL CCG ONLY* - Where antimuscarinic agents are contraindicated or not tolerant.

*FOR MORECAMBE BAY CCG ONLY* - Mirabegron is recommended second line after at least two other NICE recommended therapies have been tried and either failed or not tolerated.

*FOR GREATER PRESTON, CHORLEY & SOUTH RIBBLE CCGS ONLY* - Restricted to third line use as per TA

For preterm birth risk reduction

Vulvovaginal or vaginal atrophy in postmenopausal women

Pentosan Polysulfate Sodium for treating bladder pain (NICE TA610)